AgingResearch.NewsJoin free

Menarini Group

CompanyItaly

Menarini Group develops 2 assets, the furthest in phase 1 (MEN2312 in ER-positive HER2-negative breast cancer). Mostly small molecule acting on KAT6A, KAT6B and KIF18A; based in Italy.

2
Assets
Furthest stage
Phase 1
6
Trials
2
Signals

Pipeline

2

  • MEN2312

    Oral KAT6A and KAT6B inhibitor that blocks oestrogen-receptor signalling at the level of transcription

    Phase 1, Small molecule, KAT6A, KAT6B, ER-positive HER2-negative breast cancer

  • MEN2501

    Inhibitor of the kinesin KIF18A motor protein, for cancers with chromosome instability

    Phase 1, Small molecule, KIF18A, platinum-resistant ovarian cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials8
  • Signals2
  • Similar companies4

Papers

Intelligence